Product Development

Novo makes obesity pick as amylin/GLP-1 combo promises gastric bypass-like efficacy

With data in from five obesity programs, Novo pins hopes on amylin/GLP-1 combo

Novo is homing in on a semaglutide combination for obesity as it awaits CV outcomes data from the monotherapy that could convince more physicians to treat the condition.

Novo Nordisk is closing in on a one-two punch it believes could shift the treatment paradigm for obesity with the pick of an amylin/semaglutide combination as its next big therapy in the disease.

The combo is set to enter late-stage development in 2021, on the  heels of clinical data from a cardiovascular outcomes trial of Novo’s semaglutide monotherapy in obesity. The pharma hopes the evidence of the CVOT will persuade physicians of the